Companies: 10,795·Total market cap: $144.5T
Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

VNDANASDAQHealthcare● Active
$5.96
$-0.08(-1.24%)
Market Cap$358107272
P/E Ratio
52W High$9.94
52W Low$4.14

Vanda Pharmaceuticals Inc. (VNDA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

vnda · stock forecast · 19 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 19 Wall Street analysts in the past 3 months

SellBuy

Buy

19 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
13
Hold
5
Sell
1
Strong Sell
0
Total: 19 · Buy rate: 68.4%

12-Month Price Target

High

$21.00

Consensus

$14.25

+139.8% upside

Low

$7.50

Median: $14.25 · Last Close: $5.94

The Vanda Pharmaceuticals Inc. (VNDA) analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month VNDA price target is $14.25, representing +139.8% upside from the current price of $5.94.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $14 (139.8%)

Consensus Target

$14.25

139.8% upside

High Target

$21

253.4%

Low Target

$7.5

26.2%

Current Price

$5.94

as of today

Based on analyst price targets, the VNDA stock price prediction for the next 12 months ranges from $7.5 to $21. The consensus VNDA price forecast of $14.25 implies 139.8% upside from the current price of $5.94.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$5.812.21%

1-day model range: $5.76–$5.86. Peak: $5.86 (-2.21%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%36%64%
0Buy
5Neutral
9Sell
RSI (14)46.1Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · VNDA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$6.09SELL
MA 10$6.26SELL
MA 20$6.25SELL
MA 50$6.72SELL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $VNDA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$6.09SELL
EMA 10$6.19SELL
EMA 20$6.32SELL
EMA 50$6.81SELL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $VNDA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-05-11
Maintains
BuyBuy
HC Wainwright & Co.2026-02-23
Maintains
BuyBuy
HC Wainwright & Co.2026-01-05
Maintains
BuyBuy
Jefferies2025-12-31
Maintains
HoldHold
B. Riley Securities2025-12-31
Maintains
BuyBuy
HC Wainwright & Co.2025-11-19
Maintains
BuyBuy
Cantor Fitzgerald2025-10-30
Maintains
OverweightOverweight
HC Wainwright & Co.2025-08-21
Maintains
BuyBuy
HC Wainwright & Co.2025-05-07
Maintains
BuyBuy
HC Wainwright & Co.2025-04-01
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Vanda Pharmaceuticals Inc. (VNDA) stock. Of the recent 65 rating actions, 6 were upgrades and 8 were downgrades. 19 analysts currently cover VNDA.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

VNDA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$263M

↓ 38.2% YoY

Revenue Next Year

$356M

↑ 35.6% YoY

EPS This Year

$-2.30

EPS Next Year

$-0.87

↓ 62.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast VNDA EPS of $-2.30 for the current fiscal year, based on estimates from 4 analysts. The VNDA revenue forecast is $263M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The VNDA stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VNDA price target is $14.25 (+139.8% upside), with an analyst consensus of Buy.

The VNDA short-term stock prediction for tomorrow is $5.81 (-2.21%).

Vanda Pharmaceuticals Inc. trades on NASDAQ under the ticker VNDA. The VNDA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 68% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

VNDA forecast · 8 questions

According to 19 Wall Street analysts, the average 12-month VNDA price target is $14.25, with a high forecast of $21.00 and a low of $7.50. The median price target is shown in the chart above when available. This implies +139.8% potential upside from the current price of $5.94.

VNDA price targetWhat is VNDA price targetVNDA analyst price targetVNDA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.